Codiak BioSciences (CDAK) executive Williams sold 5,075 shares for $2,918 at $0.57
Insider transactions reported
Douglas E Williams (executive at Codiak BioSciences Inc., CDAK) reported that they sold 5,075 shares for $2,918 at $0.57, and acquired 13,667 shares between Jan 19, 2023 and Jan 20, 2023. After these transactions the filing shows 18,177 shares held directly.
- Reporting person
- Williams Douglas E
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 19, 2023 | Exercise or conversion of a derivative (M) | Common Stock1 | +13,667 | - | - | 23,252 direct |
| Jan 20, 2023 | Open-market sale (S) | Common Stock2 | -5,075 | $0.57 | $2,918 | 18,177 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 19, 2023 | Exercise or conversion of a derivative (M) | Restricted Stock UnitsOn 13,667 Common Stock3, 4 | -13,667 | - | - | 27,333 direct |
Holdings before and after
- Common Stock: 9,585 to 18,177 direct
- Restricted Stock Units: 41,000 to 27,333 direct
Footnotes from the filing
- 1. Restricted stock units ( RSUs ) convert into common stock on a one-for-one basis.
- 2. The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a sell to cover provision included in the RSU Agreement.
- 3. Each RSU represents a contingent right to receive one share of common stock.
- 4. On January 19, 2022, the reporting person was granted 41,000 RSUs, vesting in three equal annual installments beginning on the first anniversary of the grant date.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Williams report in this CDAK Form 4?
Douglas E Williams (executive at Codiak BioSciences Inc., CDAK) reported that they sold 5,075 shares for $2,918 at $0.57, and acquired 13,667 shares between Jan 19, 2023 and Jan 20, 2023. After these transactions the filing shows 18,177 shares held directly.
How many CDAK shares does Williams hold after this filing?
The filing shows 18,177 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this CDAK insider sale made under a 10b5-1 plan?
The filing's footnotes do not mention a Rule 10b5-1 trading plan.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for CDAK
Earlier insider filings at CDAK
- Jan 23, 2023SEC Form 4: Sathyanarayanan Sriram converted options into 2,834 shares and sold $622 worth of shares (1,082 units at $0.58) (withholding obligation)
- Jan 23, 2023SEC Form 4: Howze Yalonda converted options into 4,000 shares and sold $870 worth of shares (1,512 units at $0.58) (for withholding tax)
- Jan 23, 2023SEC Form 4: Barna Nicole converted options into 2,167 shares and sold $481 worth of shares (836 units at $0.57), increasing direct ownership by 20% to 8,112 units (withholding tax)
- Sep 20, 2022SEC Form 4 filed by Sathyanarayanan Sriram
- Sep 20, 2022SEC Form 4 filed by Bain Linda
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- Listed since
- 2020
Follow CDAK and get a push notification the moment its next story breaks.